Insulin Value News Today

The product is not expected on store shelves until at least next year.

Danish pharmaceutical company Novo Nordisk has announced it is lowering the U.S. list prices of several insulin products by up to 75% for people living with Type 1 and type 2 diabetes. It becomes the second drugmaker to do so, following Eli Lilly's announcement earlier this month that it was capping out-of-pocket costs to $35 a month for insulin. Novo Nordisk products include

This is a move that the company can afford to make.

The pharmaceutical giant is also expanding a program that caps insulin at $35.

Eli Lilly has announced that it is reducing the list price of its insulin by 70% and capping out-of-pocket costs at $35 a month as part of its Insulin Value Program. Effective immediately, Lilly will automatically cap out-of-pocket costs at $35 at participating retail pharmacies for people with commercial insurance using Lilly insulin. Lilly is cutting the list price of its

The cap on the diabetes medication by the drugs giant could bring cost relief to many Americans.

Adults with diabetes with commercial health insurance who use insulin manufactured by Eli Lilly and Company will have out-of-pocket costs capped at $35 per month, according to a company press release. Effective immediately, Lilly announced it will cap the out-of-pocket cost of insulin at $35 per month for U.S. residents with commercial insurance, as well those without health insurance, through

The cap on the diabetes medication by the drugs giant could bring cost relief to many Americans.

Governor Newsom unveils plans to work with a CMO to produce low-cost insulin, as most big pharma insulin is currently produced in-house.